Hyaluronic Acid for Soft Tissue Injuries

Ankle Sprains Clinical Trial

— SAFE  

Official title:

Soft Tissue Adapted Hyaluronic Acid Functional Evaluation (SAFE): A Prospective Study

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05278897
• Other study ID #: 001
• Status: Not yet recruiting
• Phase: N/A
• Start date: March 14, 2022
• Est. completion date: May 13, 2024

Study information

• Verified date: March 2022
• Source: Global Research Solutions
• Contact: Steven Phillips
• Phone: 1-289-337-8717
• Email: steve.phillips[@]myorthoevidence.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Soft Tissue Adapted Biocompatible Hyaluronic Acid, or STABHA™, has demonstrated varying degrees efficacy in patients treated for common musculoskeletal tendinopathies and ligament injuries, such as ankle sprains, lateral elbow tendinopathy, and rotator cuff tendinopathies. Factors associated with prognosis following treatment remain largely unknown. Identifying appropriate patient populations for use of STABHA™ is a necessary first step to facilitate the design of future clinical trials in the management of acute and chronic musculoskeletal soft-tissue injuries.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 200
• Est. completion date: May 13, 2024
• Est. primary completion date: May 13, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients 18 years of age or older.

2. Having a STABHA™ injection for the treatment of:

1. Acute first or second degree ankle sprain (e.g. occurred within the past 48 hours).

2. Lateral epicondylitis (tennis elbow).

3. Informed consent obtained.

Exclusion Criteria:

1. Medical contraindication to STABHA™.

2. Previous treatment with STABHA™.

3. Ankle or foot fracture.

4. Bilateral ankle sprain.

5. Previous ankle sprain in the past 12 months.

6. Prior surgical management of the ankle or elbow.

7. Current or anticipated incarceration.

8. Terminal illness with expected survival less than 90 days.

9. Currently enrolled in a study that does not permit co-enrollment.

10. Unable to obtain informed consent due to language barriers.

11. Unable to comply with the protocol.

12. Problems, in the judgment of study personnel, with maintaining follow-up with the patient.

13. Prior enrollment in the study.

14. Other reason to exclude the patient, as approved by the Sponsor.

Related Conditions & MeSH terms

• Ankle Injuries
• Ankle Sprains
• Elbow Tendinopathy
• Tendinopathy

Intervention

Device:
• Soft Tissue Adapted Biocompatible Hyaluronic Acid
1% sodium hyaluronate

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Global Research Solutions	Pendopharm

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Visual Analog Scale (VAS) Pain	A 100mm visual analog scale, with 0 representing no pain and 100 representing the worst pain imaginable. The patient will place an 'X' on the line which represents their current pain.	12 months
Secondary	EuroQol-5 Dimensions (EQ-5D)	A quality-of-life measurement instrument based on 5 dimensions of quality of life: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. This brief questionnaire determines a quality of life score between 0 and 1, where 1 represents perfect health and 0 represents death.	12 months
Secondary	12-Item Short Form Survey Version 1 (SF-12V1)	The SF-12 is a validated quality-of-life measurement tool that focuses on the impact of patient health on their everyday life. The SF-12 consists of 12 items that were developed to capture the physical and mental aspects of the patient's health status and is measured on a scale of -, with higher scores indicating better physical and mental health of the patient.	12 months
Secondary	Pain medication use	The need for the patient to take pain medication for their injury/condition will be recorded using a 4-point Likert scale in order to determine if the treatment can reduce or cease the need for pain medication from medication use at baseline.	12 months
Secondary	Adverse Events	Any adverse event experienced by the patient will be recorded at all follow-ups.	12 months